Clinical trials: Bladder
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Screening Tool, Focus Group
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the…
- Trial name
- ACCESS (NCT06412874)
- Testing
- Screening tool
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Rectal Cancer
Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging
The purpose of this study is to implement and access a newly developed bladder filling protocol for patients receiving radiotherapy for rectal cancer using imaging on the treatment unit.
- Trial name
- FILL (NCT01033682)
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Overactive Bladder
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
This Phase 3 trial will investigate the efficacy, tolerability and safety of fesoterodine fumarate (SR) (fesoterodine; SPM 907) in adult male and female subjects with overactive bladder syndrome.
- Trial name
- NCT00138723
- Testing
- SPM 907
- Sponsor
- Pfizer
Genito Urinary Cancer, Bladder Cancer
Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers
The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model.
- Conditions
- Genito Urinary Cancer, Bladder Cancer, Kidney Cancer, Prostate Cancer
- Trial name
- Immune PDX (NCT03134027)
- Testing
- Bone marrow biopsy, Tumor biopsy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Gall Stone, Common Bile Duct Calculi
Laparoendoscopic Rendezvous for Concomitant Gall Bladder Stones and Common Bile Duct Stones
Chronic calculous cholecystitis in pediatric patients leads to choledocholithiasis in about 12% of cases. These patients require removal of stones from the common bile duct.
- Conditions
- Gall Stone, Common Bile Duct Calculi, Cholecystitis, Chronic, Choledocholithiasis
- Trial name
- LERV (NCT07008170)
- Testing
- Laparoendoscopic rendezvous
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Minia University
Overactive Bladder
Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Overactive Bladder
Overactive bladder syndrome (OAB) is a prevalent disorder that affects about 10% of the adult population and > 40% of elderly. It is defined by the presence of urgency, with or without urge incontinence, in the absence of…
- Trial name
- NCT03156088
- Testing
- Sacral Neuromodulator "InterStim"
- Volunteers
- 100 people
- Sponsor
- Assiut University
Neoplasms
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
This study is for patients with cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist.
- Trial name
- NCT00487786
- Testing
- OGX-427, Docetaxel
- Where
- 3 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Achieve Life Sciences
Overactive Bladder
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
- Trial name
- VECTOR (NCT00431041)
- Testing
- solifenacin, oxybutynin immediate release
- Where
- 12 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc
Bladder Carcinoma, Infiltrative Bladder Carcinoma
A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.
- Conditions
- Bladder Carcinoma, Infiltrative Bladder Carcinoma, Cystectomy
- Trial name
- LAPAINBLAD (NCT01245660)
- Testing
- LAPATINIB
- Where
- France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Bordeaux
Overactive Bladder (OAB), Over Active Bladder
A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial
The RiSolve Trial is a prospective, single-arm, post-market clinical investigation designed to evaluate the effectiveness, usability, and safety of a prescription digital therapeutic (PDTx) for women suffering from overactive…
- Trial name
- NCT07206446
- Testing
- RiSolve
- Where
- Ireland
- Volunteers
- 46 people
- Sponsor
- University of Galway
Cesarean Delivery
Bladder Flap Technique In Elective Cesarean Section
Cesarean section is a surgical procedure used to deliver one or more babies. cesarean section is usually performed when vaginal delivery will put the mother or child's health or life at risk.
- Trial name
- NCT03016273
- Testing
- creation of bladder flap
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Assiut University
Bladder Cancer
Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer
A significant number of patients with high risk superficial bladder cancer has progression to invasive disease. No consensus exists regarding the optimal treatment to decrease the recurrence and progression rate.
- Trial name
- NCT00696579
- Testing
- BCG, gemcitabine
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- University Of Perugia
Bladder Cancer Transitional Cell Carcinoma
Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology
This study includes two semi-consecutive parts: Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples.
- Trial name
- NCT01551342
- Where
- 7 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Zetiq Technologies
Urinary Incontinence in Children
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
The primary objective is to evaluate if (1) combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if (2) combination therapy of mirabegron and solifenacin in low…
- Trial name
- NCT06551246
- Testing
- Solifenacin, Mirabegron
- Where
- 5 sites in Denmark
- Volunteers
- 236 people
- Sponsor
- University of Aarhus
Urinary Bladder, Neurogenic
Ambulatory Closed-loop Stimulation for Bladder Control
Individuals with spinal cord injury (SCI) develop neurogenic detrusor overactivity (NDO), resulting in urinary incontinence, decreased bladder capacity, and reduced quality of life.
- Trial name
- NCT05740527
- Testing
- Noninvasive electrical stimulation of genital nerves
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- MetroHealth Medical Center
Bladder Stone
Impact of Concomitant TURP on Bladder Stone Surgery Outcomes
The management of bladder stones secondary to benign prostatic hyperplasia (BPH) remains controversial regarding whether transurethral resection of the prostate (TURP) should be performed concomitantly or selectively.
- Trial name
- NCT07831486
- Testing
- Transurethral Cystolitholapaxy Alone, Transurethral Resection of the Prostate (TURP)
- Where
- Egypt
- Volunteers
- 104 people
- Sponsor
- Beni-Suef University
Urinary Bladder Cancer, Bladder Cancer
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous…
- Conditions
- Urinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms, Bladder Tumors
- Trial name
- NCT00462488
- Testing
- Vicinium
- Where
- 21 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Sesen Bio, Inc.
Urinary Tract Infection Bacterial
Evaluation of Urine Samples Obtained by Bladder Stimulation for the Diagnosis of Urinary Tract Infection in Infants
Urinary tract infection (UTI) is the most common serious bacterial infection among infants. Suprapubic aspiration and bladder catheterization are considered as the gold standard by the American Academy of Pediatrics for the…
- Trial name
- EEStiVeN (NCT03801213)
- Testing
- urinary catheterization, manual bladder stimulation technique
- Where
- 4 sites in France
- Volunteers
- 170 people
- Sponsor
- Fondation Lenval
Overactive Bladder, Neurogenic Detrusor Overactivity
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
The purpose of the study is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).
- Trial name
- NCT02526979
- Testing
- mirabegron
- Where
- 3 sites in Denmark, Poland
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Europe B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.